Navigation Links
Ex-IITian-designed Alzheimer's Drug's Human Clinical Trials Begin

Purdue University researchers have begun the first phase of human clinical trials to test the efficacy of an Alzheimer's drug designed in-house.

The drug is based on an inhibitor developed by a team of researchers at the university. The researchers say that it may help intercept and disable the disease at an early stage.

"Millions of people suffer from this devastating disease and treatment options are very limited," said Professor Arun Ghosh, who led the creation of the treatment molecule.

"Current drugs manage the symptoms, but this could be the first disease-modifying therapy. It may be able to prevent and reverse the disease," Ghosh, who did his MSc from MSc, Indian Institute of Technology, Kanpur in 1981.

CoMentis Inc., a San Francisco-based biopharmaceutical firm co-founded by Professor Ghosh and Oklahoma Medical Research Foundation (OMRF) scientist Jordan Tang, is initiating the clinical trials of the experimental drug CTS-21166.

The trial, which comprises of 48 healthy volunteers, will measure safety, tolerability, and pharmacokinetics of CTS-21166 at various doses.

Its results are expected to be out by the end of 2007, and the researchers expect to begin phase II studies in Alzheimer's patients in 2008.

In 2000, Professor Ghosh had built an inhibitor that had the ability to bind to and inactivate the beta-secretase enzyme, which is significant to the progression of Alzheimer's. Since then he has been leading the structure-based design of these inhibitors for therapeutic intervention of the disease.

His most recent work, which led to the creation of beta-secretase inhibitor CTS-21166, was published in the Journal of Medicinal Chemistry.

"The molecule is both highly potent and highly selective, meaning it does not appear to affect other enzymes important to brain function or cause harmful side effects," Professor Ghosh said.

"It took years of work and evaluation of hundreds of molecules to achieve one with the strength and safety necessary for clinical potential," he added.


'"/>




Related medicine news :

1. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
2. Decrease in testosterone levels lead to Alzheimers
3. Smokers are prone to Alzheimers
4. Over-The-Counter Drugs May Prevent Alzheimers
5. Alzheimers followed by head injury
6. Vitamin E useful for Alzheimers
7. Staying mentally energitic prevents Alzheimers
8. Researchers trick Alzheimers Enzyme
9. Drug Offers Hope for Alzheimers disease
10. Alzheimers with psychosis runs in families
11. Blood test may aid foretell Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... ... January 24, 2017 , ... Inspiration, Community & Mentorship – ... as the Fordham Institute’s High Stakes for High Achievers offer recommendations ... gifted or high-achieving students as a subgroup and reporting their results separately. Top ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost water advocate ... Global Climate Change and Your Health on Voice America, once again welcomed one ...
(Date:1/24/2017)... ... January 24, 2017 , ... A yellow fever outbreak ... the last month. Yellow fever is primarily spread through contact with infected mosquitos. The ... on how to prevent its spread. , According to multiple health organizations, the best ...
(Date:1/24/2017)... ... 24, 2017 , ... “Choosing Wisdom-Solomon’s Proverbs Reclaimed”: an ... gossip, prostitution, adultery, anger, and common sense. , “Choosing Wisdom-Solomon’s Proverbs Reclaimed” ... David Coats. In September of 1983, they flew to Haiti to focus on ...
(Date:1/24/2017)... ... ... “Mysteries Revealed On Speaking In Tongues”: an engaging and dynamic study ... “Mysteries Revealed On Speaking In Tongues” is the creation of published author, Tina Jackson, ... in Michigan. , “We need to partner with Jesus and be the voice ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... -- Aptuit, LLC, hat heute den Beginn ... General Hospital (MGH) unter Leitung von Dr. Laurence ... und Validierung neuartiger Targets in gramnegativen Bakterien.  Aptuit erhofft ... Antibiotika bei der Behandlung schwerer Infektionen entgegenwirken können. ... ...
(Date:1/24/2017)... , Jan. 23, 2017 Laboratory Markets ... global use of mass spectrometry in both clinical and ... ,MS analysis, global market size of $6.8 billion and ... next four years, profiles the use of mass spectrometry ... 21 countries. This study investigated growth in the use ...
(Date:1/24/2017)... 2017 Global Market for Pharmaceutical ... A majority of medicines & drugs produced in ... (API), and such processes require alcoholic solvents such as ... of pharmaceutical solvents continues to be concentrated in the ... (APEJ) region as leading API suppliers and ...
Breaking Medicine Technology: